1346575-54-9 Usage
Uses
Used in Pharmaceutical Industry:
1H-Indole-4-carboxylic acid, 6-bromo-3-methyl-1-(1-methylpropyl)is used as a pharmaceutical intermediate for the development of new drugs. Its indole core and unique substituents may contribute to the creation of compounds with novel therapeutic effects and selectivity.
Used in Medicinal Chemistry Research:
1H-Indole-4-carboxylic acid, 6-broMo-3-Methyl-1-(1-Methylpropyl)serves as a valuable target in medicinal chemistry research, where its structure can be further modified and optimized to enhance its pharmacological properties. The bromine and methyl groups may be particularly interesting for exploring structure-activity relationships and potential drug candidates.
Check Digit Verification of cas no
The CAS Registry Mumber 1346575-54-9 includes 10 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 7 digits, 1,3,4,6,5,7 and 5 respectively; the second part has 2 digits, 5 and 4 respectively.
Calculate Digit Verification of CAS Registry Number 1346575-54:
(9*1)+(8*3)+(7*4)+(6*6)+(5*5)+(4*7)+(3*5)+(2*5)+(1*4)=179
179 % 10 = 9
So 1346575-54-9 is a valid CAS Registry Number.
1346575-54-9Relevant academic research and scientific papers
SUBSTITUTED BENZENE AND 6,5-FUSED BICYCLIC HETEROARYL COMPOUNDS
-
, (2016/05/02)
The present invention relates to substituted benzene compounds and bicyclic heteroaryl compounds. The present invention also relates to pharmaceutical compositions containing these compounds and methods of treating cancer by administering these compounds and pharmaceutical compositions to subjects in need thereof. The present invention also relates to the use of such compounds for research or other non-therapeutic purposes.
METHOD OF TREATMENT
-
, (2014/09/29)
The present invention relates to a method of treating T cell mediated inflammatory immune diseases or T cell mediated hypersensitivity diseases, which comprises administering to a human in need thereof an effective amount of a compound which inhibits EZH2 and/or EZH1, or a pharmaceutically acceptable salt thereof.
